Advertisement

Acta Neuropathologica

, Volume 131, Issue 2, pp 211–234 | Cite as

Infections, inflammation and epilepsy

  • Annamaria Vezzani
  • Robert S. Fujinami
  • H. Steve White
  • Pierre-Marie Preux
  • Ingmar Blümcke
  • Josemir W. Sander
  • Wolfgang Löscher
Review

Abstract

Epilepsy is the tendency to have unprovoked epileptic seizures. Anything causing structural or functional derangement of brain physiology may lead to seizures, and different conditions may express themselves solely by recurrent seizures and thus be labelled “epilepsy.” Worldwide, epilepsy is the most common serious neurological condition. The range of risk factors for the development of epilepsy varies with age and geographic location. Congenital, developmental and genetic conditions are mostly associated with the development of epilepsy in childhood, adolescence and early adulthood. Head trauma, infections of the central nervous system (CNS) and tumours may occur at any age and may lead to the development of epilepsy. Infections of the CNS are a major risk factor for epilepsy. The reported risk of unprovoked seizures in population-based cohorts of survivors of CNS infections from developed countries is between 6.8 and 8.3 %, and is much higher in resource-poor countries. In this review, the various viral, bacterial, fungal and parasitic infectious diseases of the CNS which result in seizures and epilepsy are discussed. The pathogenesis of epilepsy due to brain infections, as well as the role of experimental models to study mechanisms of epileptogenesis induced by infectious agents, is reviewed. The sterile (non-infectious) inflammatory response that occurs following brain insults is also discussed, as well as its overlap with inflammation due to infections, and the potential role in epileptogenesis. Furthermore, autoimmune encephalitis as a cause of seizures is reviewed. Potential strategies to prevent epilepsy resulting from brain infections and non-infectious inflammation are also considered.

Keywords

Seizures Epileptogenesis Central nervous system Cytokines Meningitis Encephalitis Neuroinfectiology Virus Bacteria Fungi Parasites 

Notes

Acknowledgments

AV and WL have received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under Grant Agreement No. 602102 (EPITARGET). WL’s research is supported by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony (Germany) and AV’s research by the Fondazione Monzino. RSF is supported by NIH R01 NS065714. JWS is based at the UCLH/UCL Comprehensive Bio-Medical Research Centre which received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. JWS receives research support from the Dr. Marvin Weil Epilepsy Research Fund and the UK Epilepsy Society. IB received funding from the European Union’s Seventh Framework Program under Grant Agreement No. 602531 (DESIRE). We thank Dr. Ingo Gerhauser, Christopher Käufer and Dr. Sonja Bröer for preparing the photomicrographs in Fig. 11, Drs. Arturo Carpio Rodas, Indran Davagnanam and Chandrashekar Hoskote for providing brain images of patients, and Profs. Wolfgang Brück, Roland Nau and Thomas Henze for providing brain sections or photomicrographs of patients. We are grateful to Dr. Gail S Bell for critically reviewing the manuscript.

References

  1. 1.
    Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J (2005) Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128:1764–1777CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Annegers JF, Hauser WA, Beghi E, Nicolosi A, Kurland LT (1988) The risk of unprovoked seizures after encephalitis and meningitis. Neurology 38:1407–1410CrossRefPubMedGoogle Scholar
  3. 3.
    Annegers JF, Rocca WA, Hauser WA (1996) Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin Proc 71:570–575CrossRefPubMedGoogle Scholar
  4. 4.
    Armangue T, Petit-Pedrol M, Dalmau J (2012) Autoimmune encephalitis in children. J Child Neurol 27:1460–1469CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aronica E, Boer K, van Vliet EA, Redeker S, Baayen JC, Spliet WG, van Rijen PC, Troost D, da Silva FH, Wadman WJ, Gorter JA (2007) Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis 26:497–511CrossRefPubMedGoogle Scholar
  6. 6.
    Auvin S, Shin D, Mazarati A, Nakagawa J, Miyamoto J, Sankar R (2007) Inflammation exacerbates seizure-induced injury in the immature brain. Epilepsia 48(Suppl 5):27–34CrossRefPubMedGoogle Scholar
  7. 7.
    Auvin S, Mazarati A, Shin D, Sankar R (2010) Inflammation enhances epileptogenesis in the developing rat brain. Neurobiol Dis 40:303–310CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bale JF Jr (2015) Virus and immune-mediated encephalitides: epidemiology, diagnosis, treatment, and prevention. Pediatr Neurol 53:3–12CrossRefPubMedGoogle Scholar
  9. 9.
    Balosso S, Ravizza T, Perego C, Peschon J, Campbell IL, De Simoni MG, Vezzani A (2005) Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann Neurol 57:804–812CrossRefPubMedGoogle Scholar
  10. 10.
    Balosso S, Ravizza T, Aronica E, Vezzani A (2013) The dual role of TNF-alpha and its receptors in seizures. Exp Neurol 247:267–271CrossRefPubMedGoogle Scholar
  11. 11.
    Barker-Haliski ML, Dahle EJ, Heck TD, Pruess TH, Vanegas F, Wilcox KS, White HS (2015) Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler’s murine encephalomyelitis virus mouse model. J Pharmacol Exp Ther 353:318–329CrossRefPubMedGoogle Scholar
  12. 12.
    Bauer J, Vezzani A, Bien CG (2012) Epileptic encephalitis: the role of the innate and adaptive immune system. Brain Pathol 22:412–421CrossRefPubMedGoogle Scholar
  13. 13.
    Bauer S, Cepok S, Todorova-Rudolph A, Nowak M, Koller M, Lorenz R, Oertel WH, Rosenow F, Hemmer B, Hamer HM (2009) Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res 86:82–88CrossRefPubMedGoogle Scholar
  14. 14.
    Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA (2010) Recommendation for a definition of acute symptomatic seizure. Epilepsia 51:671–675CrossRefPubMedGoogle Scholar
  15. 15.
    Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51:676–685CrossRefPubMedGoogle Scholar
  16. 16.
    Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5CrossRefPubMedGoogle Scholar
  17. 17.
    Bien CG, Elger CE (2007) Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav 10:529–538CrossRefPubMedGoogle Scholar
  18. 18.
    Birbeck GL, Molyneux ME, Kaplan PW, Seydel KB, Chimalizeni YF, Kawaza K, Taylor TE (2010) Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. Lancet Neurol 9:1173–1181CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bittencourt PR, Sander JW and Mazer S (1999) Viral, bacterial, fungal and parasitic infections associated with seizure disorders. In: Meinardi H (ed) Handbook of clinical neurology, The epilepsies, vol 72. Elsevier, Amsterdam, pp 145–174Google Scholar
  20. 20.
    Blümcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi A, Bernasconi N, Bien CG, Cendes F, Coras R, Cross JH, Jacques TS, Kahane P, Mathern GW, Miyata H, Moshe SL, Oz B, Ozkara C, Perucca E, Sisodiya S, Wiebe S, Spreafico R (2013) International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 54:1315–1329CrossRefPubMedGoogle Scholar
  21. 21.
    Brouwer MC, Tunkel AR, McKhann GM, van de Beek D (2014) Brain abscess. N Engl J Med 371:447–456CrossRefPubMedGoogle Scholar
  22. 22.
    Bröer S, Haist V, Gerhauser I, Bankstahl M, Ulrich R, Brandt C, Löscher W, Baumgärtner W (2014) Viral encephalitis-induced epilepsy: pathogenetic studies with the BeAn strain of Theiler’s murine encephalomyelitis virus (TMEV). In: First N-RENNT Symposium on Neuroinfectiology, March 31–April 1, 2014, Hannover (Abstract) Google Scholar
  23. 23.
    Bruner DI, Littlejohn L, Pritchard A (2012) Subdural empyema presenting with seizure, confusion, and focal weakness. West J Emerg Med 13:509–511CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bruno E, Bartoloni A, Zammarchi L, Strohmeyer M, Bartalesi F, Bustos JA, Santivanez S, Garcia HH, Nicoletti A (2013) Epilepsy and neurocysticercosis in Latin America: a systematic review and meta-analysis. PLoS Negl Trop Dis 7:e2480CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Buckingham SC, Ramos TN, Barnum SR (2014) Complement C5-deficient mice are protected from seizures in experimental cerebral malaria. Epilepsia 55:e139–e142CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, Vincent A (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50:73–78CrossRefPubMedGoogle Scholar
  27. 27.
    Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci 90:10061–10065CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cendes F, Sakamoto AC, Spreafico R, Bingaman W, Becker AJ (2014) Epilepsies associated with hippocampal sclerosis. Acta Neuropathol 128:21–37CrossRefPubMedGoogle Scholar
  29. 29.
    Choy M, Dube CM, Patterson K, Barnes SR, Maras P, Blood AB, Hasso AN, Obenaus A, Baram TZ (2014) A novel, noninvasive, predictive epilepsy biomarker with clinical potential. J Neurosci 34:8672–8684CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Choy M, Dube CM, Ehrengruber M, Baram TZ (2014) Inflammatory processes, febrile seizures, and subsequent epileptogenesis. Epilepsy Curr 14:15–22CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Colebunders R, Post R, O’Neill S, Haesaert G, Opar B, Lakwo T, Laudisoit A, Hendy A (2015) Nodding syndrome since 2012: recent progress, challenges and recommendations for future research. Trop Med Int Health 20:194–200CrossRefPubMedGoogle Scholar
  32. 32.
    Correll CM (2013) Antibodies in epilepsy. Curr Neurol Neurosci Rep 13:348CrossRefPubMedGoogle Scholar
  33. 33.
    Corsellis JA, Goldberg GJ, Norton AR (1968) “Limbic encephalitis” and its association with carcinoma. Brain 91:481–496CrossRefPubMedGoogle Scholar
  34. 34.
    Cusick MF, Libbey JE, Patel DC, Doty DJ, Fujinami RS (2013) Infiltrating macrophages are key to the development of seizures following virus infection. J Virol 87:1849–1860CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, De Luigi A, Garattini S, Vezzani A (2000) Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 12:2623–2633CrossRefPubMedGoogle Scholar
  37. 37.
    de Souza JB, Hafalla JC, Riley EM, Couper KN (2010) Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology 137:755–772CrossRefPubMedGoogle Scholar
  38. 38.
    Del Brutto OH (2008) Infections and inflammatory diseases. In: Engel JJ, Pedley TA (eds) Epilepsy: a comprehensive textbook, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 2643–2652Google Scholar
  39. 39.
    Desena A, Graves D, Warnack W, Greenberg BM (2014) Herpes simplex encephalitis as a potential cause of anti-N-methyl-d-aspartate receptor antibody encephalitis: report of 2 cases. JAMA Neurol 71:344–346CrossRefPubMedGoogle Scholar
  40. 40.
    Donati D, Akhyani N, Fogdell-Hahn A, Cermelli C, Cassiani-Ingoni R, Vortmeyer A, Heiss JD, Cogen P, Gaillard WD, Sato S, Theodore WH, Jacobson S (2003) Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. Neurology 61:1405–1411CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Dube C, Vezzani A, Behrens M, Bartfai T, Baram TZ (2005) Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol 57:152–155CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Dube CM, Ravizza T, Hamamura M, Zha Q, Keebaugh A, Fok K, Andres AL, Nalcioglu O, Obenaus A, Vezzani A, Baram TZ (2010) Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J Neurosci 30:7484–7494CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Elbers JM, Bitnun A, Richardson SE, Ford-Jones EL, Tellier R, Wald RM, Petric M, Kolski H, Heurter H, MacGregor D (2007) A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease? Pediatrics 119:e399–e407CrossRefPubMedGoogle Scholar
  44. 44.
    Epstein LG, Shinnar S, Hesdorffer DC, Nordli DR, Hamidullah A, Benn EK, Pellock JM, Frank LM, Lewis DV, Moshe SL, Shinnar RC, Sun S (2012) Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia 53:1481–1488CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Eriksson C, Van Dam AM, Lucassen PJ, Bol JG, Winblad B, Schultzberg M (1999) Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 93:915–930CrossRefPubMedGoogle Scholar
  46. 46.
    Eriksson C, Tehranian R, Iverfeldt K, Winblad B, Schultzberg M (2000) Increased expression of mRNA encoding interleukin-1beta and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. J Neurosci Res 60:266–279CrossRefPubMedGoogle Scholar
  47. 47.
    Esposito L, Drexler JF, Braganza O, Doberentz E, Grote A, Widman G, Drosten C, Eis-Hubinger AM, Schoch S, Elger CE, Becker AJ, Niehusmann P (2015) Large-scale analysis of viral nucleic acid spectrum in temporal lobe epilepsy biopsies. Epilepsia 56:234–243CrossRefPubMedGoogle Scholar
  48. 48.
    Feng ZH, Hao J, Ye L, Dayao C, Yan N, Yan Y, Chu L, Shi FD (2011) Overexpression of mu-calpain in the anterior temporal neocortex of patients with intractable epilepsy correlates with clinicopathological characteristics. Seizure 20:395–401CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Fiala M, Avagyan H, Merino JJ, Bernas M, Valdivia J, Espinosa-Jeffrey A, Witte M, Weinand M (2013) Chemotactic and mitogenic stimuli of neuronal apoptosis in patients with medically intractable temporal lobe epilepsy. Pathophysiology 20:59–69CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482CrossRefPubMedGoogle Scholar
  51. 51.
    Galic MA, Riazi K, Pittman QJ (2012) Cytokines and brain excitability. Front Neuroendocrinol 33:116–125CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Garcia HH, Del Brutto OH (2012) Infection and inflammation. Handb Clin Neurol 108:601–620CrossRefPubMedGoogle Scholar
  53. 53.
    Garcia HH, Nash TE, Del Brutto OH (2014) Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 13:1202–1215CrossRefPubMedGoogle Scholar
  54. 54.
    Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Uceyler N, Fouquet W, Gerlach M, Meinck HM, Siren AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C (2010) Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 133:3166–3180CrossRefPubMedGoogle Scholar
  55. 55.
    Gibbons MB, Smeal RM, Takahashi DK, Vargas JR, Wilcox KS (2013) Contributions of astrocytes to epileptogenesis following status epilepticus: opportunities for preventive therapy? Neurochem Int 63:660–669CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Graus F, Saiz A, Lai M, Bruna J, Lopez F, Sabater L, Blanco Y, Rey MJ, Ribalta T, Dalmau J (2008) Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 71:930–936CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Gurung P, Lukens JR, Kanneganti TD (2015) Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med 21:193–201CrossRefPubMedGoogle Scholar
  58. 58.
    Heinemann U, Kaufer D, Friedman A (2012) Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia 60:1251–1257CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Iori V, Maroso M, Rizzi M, Iyer AM, Vertemara R, Carli M, Agresti A, Antonelli A, Bianchi ME, Aronica E, Ravizza T, Vezzani A (2013) Receptor for advanced glycation endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis 58:102–114CrossRefPubMedGoogle Scholar
  60. 60.
    Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133:2734–2748CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A (2010) N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, Zagami S, Bleasel A, Somerville ER, Smith SM, Vincent A (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900CrossRefPubMedGoogle Scholar
  63. 63.
    Kaiser C, Pion SD, Boussinesq M (2013) Case-control studies on the relationship between onchocerciasis and epilepsy: systematic review and meta-analysis. PLoS Negl Trop Dis 7:e2147CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Kakoti G, Dutta P, Ram DB, Borah J, Mahanta J (2013) Clinical profile and outcome of Japanese encephalitis in children admitted with acute encephalitis syndrome. Biomed Res Int 2013:152656PubMedPubMedCentralGoogle Scholar
  65. 65.
    Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, Nutman TB, Ngugi AK, Odhiambo R, Wagner RG, Kakooza-Mwesige A, Owusu-Agyei S, Ae-Ngibise K, Masanja H, Osier FH, Odermatt P, Newton CR (2014) Exposure to multiple parasites is associated with the prevalence of active convulsive epilepsy in sub-Saharan Africa. PLoS Negl Trop Dis 8:e2908CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Kirkman NJ, Libbey JE, Wilcox KS, White HS, Fujinami RS (2010) Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia 51:454–464CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Kobow K, Blumcke I (2014) Epigenetic mechanisms in epilepsy. Prog Brain Res 213:279–316CrossRefPubMedGoogle Scholar
  68. 68.
    Kwon YS, Pineda E, Auvin S, Shin D, Mazarati A, Sankar R (2013) Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation 10:30CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Libbey JE, Kirkman NJ, Smith MC, Tanaka T, Wilcox KS, White HS, Fujinami RS (2008) Seizures following picornavirus infection. Epilepsia 49:1066–1074CrossRefPubMedGoogle Scholar
  70. 70.
    Libbey JE, Kirkman NJ, Wilcox KS, White HS, Fujinami RS (2010) Role for complement in the development of seizures following acute viral infection. J Virol 84:6452–6460CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Libbey JE, Kennett NJ, Wilcox KS, White HS, Fujinami RS (2011) Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol 85:6913–6922CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Libbey JE, Fujinami RS (2011) Neurotropic viral infections leading to epilepsy: focus on Theiler’s murine encephalomyelitis virus. Future Virol 6:1339–1350CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Linsuwanon P, Puenpa J, Huang SW, Wang YF, Mauleekoonphairoj J, Wang JR, Poovorawan Y (2014) Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J Biomed Sci 21:16CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Loup F, Wieser HG, Yonekawa Y, Aguzzi A, Fritschy JM (2000) Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy. J Neurosci 20:5401–5419PubMedGoogle Scholar
  75. 75.
    Lowenstein DH (2005) Treatment options for status epilepticus. Curr Opin Pharmacol 5:334–339CrossRefPubMedGoogle Scholar
  76. 76.
    Lowenstein DH (2009) Epilepsy after head injury: an overview. Epilepsia 50(Suppl 2):4–9CrossRefPubMedGoogle Scholar
  77. 77.
    Lowenstein DH, Walker M, Waterhouse E (2014) Status epilepticus in the setting of acute encephalitis. Epilepsy Curr 14:43–49CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Löscher W, Gernert M, Heinemann U (2008) Cell and gene therapies in epilepsy–promising avenues or blind alleys? Trends Neurosci 31:62–73CrossRefPubMedGoogle Scholar
  79. 79.
    Löscher W, Brandt C (2010) Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 62:668–700CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Löscher W, Klitgaard H, Twyman RE, Schmidt D (2013) New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov 12:757–776CrossRefPubMedGoogle Scholar
  81. 81.
    Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J (2011) Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. J Neurol 258:27–33CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J (2007) Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 61:544–551CrossRefPubMedGoogle Scholar
  83. 83.
    Marchi N, Granata T, Janigro D (2014) Inflammatory pathways of seizure disorders. Trends Neurosci 37:55–65CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Marin B, Boussinesq M, Druet-Cabanac M, Kamgno J, Bouteille B, Preux PM (2006) Onchocerciasis-related epilepsy? Prospects at a time of uncertainty. Trends Parasitol 22:17–20CrossRefPubMedGoogle Scholar
  85. 85.
    Marks DA, Kim J, Spencer DD, Spencer SS (1992) Characteristics of intractable seizures following meningitis and encephalitis. Neurology 42:1513–1518CrossRefPubMedGoogle Scholar
  86. 86.
    Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, Manfredi AA, Bianchi ME, Vezzani A (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 16:413–419CrossRefPubMedGoogle Scholar
  87. 87.
    Maroso M, Balosso S, Ravizza T, Iori V, Wright CI, French J, Vezzani A (2011) Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8:304–315CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A (2011) Interleukin-1 type 1 receptor/toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. J Intern Med 270:319–326CrossRefPubMedGoogle Scholar
  89. 89.
    Michael BD, Solomon T (2012) Seizures and encephalitis: clinical features, management, and potential pathophysiologic mechanisms. Epilepsia 53(Suppl 4):63–71CrossRefPubMedGoogle Scholar
  90. 90.
    Misra UK, Tan CT, Kalita J (2008) Viral encephalitis and epilepsy. Epilepsia 49(Suppl 6):13–18CrossRefPubMedGoogle Scholar
  91. 91.
    Miya K, Takahashi Y, Mori H (2014) Anti-NMDAR autoimmune encephalitis. Brain Dev 36:645–652CrossRefPubMedGoogle Scholar
  92. 92.
    Morin-Brureau M, Lebrun A, Rousset MC, Fagni L, Bockaert J, de Bock F, Lerner-Natoli M (2011) Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: role of VEGF signaling pathways. J Neurosci 31:10677–10688CrossRefPubMedGoogle Scholar
  93. 93.
    Nash TE, Mahanty S, Loeb JA, Theodore WH, Friedman A, Sander JW, Singh G, Cavalheiro E, Del Brutto OH, Takayanagui OM, Fleury A, Verastegui M, Preux PM, Montano S, Pretell EJ, White AC Jr, Gonzales AE, Gilman RH, Garcia HH (2015) Neurocysticercosis: a natural human model of epileptogenesis. Epilepsia 56:177–183CrossRefPubMedGoogle Scholar
  94. 94.
    Ngoungou EB, Koko J, Druet-Cabanac M, Assengone-Zeh-Nguema Y, Launay MN, Engohang E, Moubeka-Mounguengui M, Kouna-Ndouongo P, Loembe PM, Preux PM, Kombila M (2006) Cerebral malaria and sequelar epilepsy: first matched case-control study in Gabon. Epilepsia 47:2147–2153CrossRefPubMedGoogle Scholar
  95. 95.
    Ngoungou EB, Dulac O, Poudiougou B, Druet-Cabanac M, Dicko A, Mamadou TA, Coulibaly D, Farnarier G, Tuillas M, Keita MM, Kombila M, Doumbo OK, Preux PM (2006) Epilepsy as a consequence of cerebral malaria in area in which malaria is endemic in Mali, West Africa. Epilepsia 47:873–879PubMedGoogle Scholar
  96. 96.
    Ngoungou EB, Bhalla D, Nzoghe A, Darde ML, Preux PM (2015) Toxoplasmosis and epilepsy—systematic review and meta analysis. PLoS Negl Trop Dis 9:e0003525CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR (2010) Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 51:883–890CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR (2013) Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurol 12:253–263CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Niehusmann P, Mittelstaedt T, Bien CG, Drexler JF, Grote A, Schoch S, Becker AJ (2010) Presence of human herpes virus 6 DNA exclusively in temporal lobe epilepsy brain tissue of patients with history of encephalitis. Epilepsia 51:2478–2483CrossRefPubMedGoogle Scholar
  100. 100.
    Noe FM, Polascheck N, Frigerio F, Bankstahl M, Ravizza T, Marchini S, Beltrame L, Bandero CR, Löscher W, Vezzani A (2013) Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 59:183–193CrossRefPubMedGoogle Scholar
  101. 101.
    Oostenbrink R, Moons KG, Derksen-Lubsen G, Grobbee DE, Moll HA (2002) Early prediction of neurological sequelae or death after bacterial meningitis. Acta Paediatr 91:391–398CrossRefPubMedGoogle Scholar
  102. 102.
    Osborn MK, Steinberg JP (2007) Subdural empyema and other suppurative complications of paranasal sinusitis. Lancet Infect Dis 7:62–67CrossRefPubMedGoogle Scholar
  103. 103.
    Pal DK, Carpio A, Sander JW (2000) Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry 68:137–143CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Pernhorst K, Herms S, Hoffmann P, Cichon S, Schulz H, Sander T, Schoch S, Becker AJ, Grote A (2013) TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue. Seizure 22:675–678CrossRefPubMedGoogle Scholar
  105. 105.
    Pion SD, Kaiser C, Boutros-Toni F, Cournil A, Taylor MM, Meredith SE, Stufe A, Bertocchi I, Kipp W, Preux PM, Boussinesq M (2009) Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys. PLoS Negl Trop Dis 3:e461CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Pitkänen A, Engel J Jr (2014) Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics 11:231–241CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F (2003) Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 54:530–533CrossRefPubMedGoogle Scholar
  108. 108.
    Quattrocchi G, Nicoletti A, Marin B, Bruno E, Druet-Cabanac M, Preux PM (2012) Toxocariasis and epilepsy: systematic review and meta-analysis. PLoS Negl Trop Dis 6:e1775CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Quet F, Guerchet M, Pion SD, Ngoungou EB, Nicoletti A, Preux PM (2010) Meta-analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia 51:830–837CrossRefPubMedGoogle Scholar
  110. 110.
    Ramanathan S, Mohammad SS, Brilot F, Dale RC (2014) Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci 21:722–730CrossRefPubMedGoogle Scholar
  111. 111.
    Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, Vezzani A, Aronica E (2006) The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 24:128–143CrossRefPubMedGoogle Scholar
  112. 112.
    Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A (2008) Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 29:142–160CrossRefPubMedGoogle Scholar
  113. 113.
    Reid AY, Riazi K, Campbell TG, Pittman QJ (2013) Increased excitability and molecular changes in adult rats after a febrile seizure. Epilepsia 54:e45–e48CrossRefPubMedGoogle Scholar
  114. 114.
    Riazi K, Galic MA, Pittman QJ (2010) Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res 89:34–42CrossRefPubMedGoogle Scholar
  115. 115.
    Riazi K, Galic MA, Kentner AC, Reid AY, Sharkey KA, Pittman QJ (2015) Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation. J Neurosci 35:4942–4952CrossRefPubMedGoogle Scholar
  116. 116.
    Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R (2014) Cyclooxygenase-2 in epilepsy. Epilepsia 55:17–25CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131:2553–2563CrossRefPubMedGoogle Scholar
  118. 118.
    Sander JW, Perucca E (2003) Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand Suppl 180:16–22CrossRefPubMedGoogle Scholar
  119. 119.
    Sander JW (2004) Infectious agents and epilepsy. In: Knobler S, O’Connor S, Lemon SM, Najafi M (eds) The infectious etiology of chronic diseases: defining the relationship, enhancing the research and mitigating the effects. The National Academies Press, Washington, pp 93–99Google Scholar
  120. 120.
    Seebohm G, Piccini I, Strutz-Seebohm N (2015) Paving the way to understand autoantibody-mediated epilepsy on the molecular level. Front Neurol 6:149CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Serpa JA, White AC Jr (2012) Neurocysticercosis in the United States. Pathog Glob Health 106:256–260CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Shorvon S, Guerrini R (2010) Acute symptomatic seizures–should we retain the term? Epilepsia 51:722–723CrossRefPubMedGoogle Scholar
  123. 123.
    Silverman MA, Misasi J, Smole S, Feldman HA, Cohen AB, Santagata S, McManus M, Ahmed AA (2013) Eastern equine encephalitis in children, Massachusetts and New Hampshire, USA, 1970–2010. Emerg Infect Dis 19:194–201CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Singhi P (2011) Infectious causes of seizures and epilepsy in the developing world. Dev Med Child Neurol 53:600–609CrossRefPubMedGoogle Scholar
  125. 125.
    Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318:1012–1020CrossRefPubMedGoogle Scholar
  126. 126.
    Stewart KA, Wilcox KS, Fujinami RS, White HS (2010) Development of postinfection epilepsy after Theiler’s virus infection of C57BL/6 mice. J Neuropathol Exp Neurol 69:1210–1219CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Striano P, Perruolo G, Errichiello L, Formisano P, Beguinot F, Zara F, Striano S (2008) Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes. Ann Neurol 63:127–128CrossRefPubMedGoogle Scholar
  128. 128.
    Stringer JL (2006) Models available for infection-induced seizures. In: Pitkänen A, Schwartzkroin PA, Moshé SL (eds) Models of seizures and epilepsy. Elsevier, Burlington, pp 521–526CrossRefGoogle Scholar
  129. 129.
    Tsunoda I, Fujinami RS (1996) Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler’s murine encephalomyelitis virus. J Neuropathol Exp Neurol 55:673–686CrossRefPubMedGoogle Scholar
  130. 130.
    Tsunoda I, Fujinami RS (2010) Neuropathogenesis of Theiler’s murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J Neuroimmune Pharmacol 5:355–369CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Uludag IF, Duksal T, Tiftikcioglu BI, Zorlu Y, Ozkaya F, Kirkali G (2015) IL-1beta, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure 26:22–25CrossRefPubMedGoogle Scholar
  132. 132.
    Umpierre AD, Remigio GJ, Dahle EJ, Bradford K, Alex AB, Smith MD, West PJ, White HS, Wilcox KS (2014) Impaired cognitive ability and anxiety-like behavior following acute seizures in the Theiler’s virus model of temporal lobe epilepsy. Neurobiol Dis 64:98–106CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Verboon-Maciolek MA, Krediet TG, Gerards LJ, Fleer A, van Loon TM (2005) Clinical and epidemiologic characteristics of viral infections in a neonatal intensive care unit during a 12-year period. Pediatr Infect Dis J 24:901–904CrossRefPubMedGoogle Scholar
  134. 134.
    Verboon-Maciolek MA, Krediet TG, Gerards LJ, De Vries LS, Groenendaal F, van Loon AM (2008) Severe neonatal parechovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J 27:241–245CrossRefPubMedGoogle Scholar
  135. 135.
    Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, De Simoni MG, Sperk G, Andell-Jonsson S, Lundkvist J, Iverfeldt K, Bartfai T (2000) Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci 97:11534–11539CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Vezzani A, Balosso S, Maroso M, Zardoni D, Noe F, Ravizza T (2010) ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig Drugs 11:43–50PubMedGoogle Scholar
  137. 137.
    Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T (2011) IL-1 receptor/toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 25:1281–1289CrossRefPubMedGoogle Scholar
  138. 138.
    Vezzani A, Friedman A (2011) Brain inflammation as a biomarker in epilepsy. Biomark Med 5:607–614CrossRefPubMedPubMedCentralGoogle Scholar
  139. 139.
    Vezzani A, Friedman A, Dingledine RJ (2013) The role of inflammation in epileptogenesis. Neuropharmacology 69:16–24CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Vezzani A, Aronica E, Mazarati A, Pittman QJ (2013) Epilepsy and brain inflammation. Exp Neurol 244:11–21CrossRefPubMedGoogle Scholar
  141. 141.
    Vezzani A, Viviani B (2015) Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 96:70–82CrossRefPubMedGoogle Scholar
  142. 142.
    Vezzani A (2015) Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis? Expert Opin Drug Saf 14:583–592CrossRefPubMedGoogle Scholar
  143. 143.
    Vooturi S, Jayalakshmi S, Sahu S, Mohandas S (2014) Prognosis and predictors of outcome of refractory generalized convulsive status epilepticus in adults treated in neurointensive care unit. Clin Neurol Neurosurg 126:7–10CrossRefPubMedGoogle Scholar
  144. 144.
    Weinberg MS, Blake BL, McCown TJ (2013) Opposing actions of hippocampus TNFalpha receptors on limbic seizure susceptibility. Exp Neurol 247:429–437CrossRefPubMedPubMedCentralGoogle Scholar
  145. 145.
    Wenceslau CF, McCarthy CG, Goulopoulou S, Szasz T, NeSmith EG, Webb RC (2013) Mitochondrial-derived N-formyl peptides: novel links between trauma, vascular collapse and sepsis. Med Hypotheses 81:532–535CrossRefPubMedGoogle Scholar
  146. 146.
    Winkler AS (2012) Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management. Pathog Glob Health 106:261–274CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Winkler AS, Friedrich K, Velicheti S, Dharsee J, Konig R, Nassri A, Meindl M, Kidunda A, Muller TH, Jilek-Aall L, Matuja W, Gotwald T, Schmutzhard E (2013) MRI findings in people with epilepsy and nodding syndrome in an area endemic for onchocerciasis: an observational study. Afr Health Sci 13:529–540PubMedPubMedCentralGoogle Scholar
  148. 148.
    Xiong ZQ, Qian W, Suzuki K, McNamara JO (2003) Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 23:955–960PubMedGoogle Scholar
  149. 149.
    Zattoni M, Mura ML, Deprez F, Schwendener RA, Engelhardt B, Frei K, Fritschy JM (2011) Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci 31:4037–4050CrossRefPubMedGoogle Scholar
  150. 150.
    Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, Matsui M, Kato N (2012) Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 45:610–615CrossRefPubMedGoogle Scholar
  151. 151.
    Zurolo E, Iyer A, Maroso M, Carbonell C, Anink JJ, Ravizza T, Fluiter K, Spliet WG, van Rijen PC, Vezzani A, Aronica E (2011) Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 134:1015–1032CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Annamaria Vezzani
    • 1
  • Robert S. Fujinami
    • 2
  • H. Steve White
    • 3
  • Pierre-Marie Preux
    • 4
    • 5
    • 6
  • Ingmar Blümcke
    • 7
  • Josemir W. Sander
    • 8
    • 9
  • Wolfgang Löscher
    • 10
    • 11
  1. 1.Department of NeuroscienceIRCCS-“Mario Negri” Institute for Pharmacological ResearchMilanItaly
  2. 2.Department of PathologyUniversity of UtahSalt Lake CityUSA
  3. 3.Department of PharmacologyUniversity of UtahSalt Lake CityUSA
  4. 4.INSERM UMR1094, Tropical NeuroepidemiologyLimogesFrance
  5. 5.Institute of Neuroepidemiology and Tropical NeurologySchool of Medicine, University of LimogesLimogesFrance
  6. 6.Center of Epidemiology, Biostatistics, and Research Methodology, CHU LimogesLimogesFrance
  7. 7.Department of NeuropathologyUniversity Hospital ErlangenErlangenGermany
  8. 8.NIHR University College London Hospitals Biomedical Research Centre, UCL Institute of NeurologyLondonUK
  9. 9.Stichting Epilepsie Instellingen Nederland (SEIN)HeemstedeThe Netherlands
  10. 10.Department of Pharmacology, Toxicology, and PharmacyUniversity of Veterinary MedicineHannoverGermany
  11. 11.Center for Systems NeuroscienceHannoverGermany

Personalised recommendations